Genomic Abnormalities Acquired in the Blastic Transformation of Splenic Marginal Zone B-cell Lymphoma-Reference-Cited by-同舟云学术

Genomic Abnormalities Acquired in the Blastic Transformation of Splenic Marginal Zone B-cell Lymphoma

Published:2003-01 Issue:3 Volume:44 Page:459-464
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Martinez-Climent Jose A.,Sanchez-Izquierdo Dolors,Sarsotti Elena,Blesa David,Benet Isabel,Climent Joan,Vizcarra Esperanza,Marugan Isabel,Terol Maria J.,Sole Francesc,Cigudosa Juan C.,Siebert Reiner,Dyer Martin J.S.,García-Conde Javier

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.1080/1042819021000055129

Reference25 articles.

1. The World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues

2. A Clinicopathological Study of 13 Cases

3. Splenic marginal zone lymphoma with increased number of blasts: An aggressive variant?

4. Blastic Transformation of Splenic Marginal Zone B-Cell Lymphoma

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms;Molecular Cancer Therapeutics;2023-12-05

2. Standardized assays to monitor drug sensitivity in hematologic cancers;Cell Death Discovery;2023-12-01

3. Primary cutaneous blastic marginal zone lymphoma: A comprehensive clinical, light microscopic, phenotypic and cytogenetic appraisal;Annals of Diagnostic Pathology;2023-04

4. Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors;Journal of Clinical Medicine;2023-01-04

5. ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms;2023-01-02